Robert G Strachan

US Patent:

44252692, Jan 10, 1984

Filed:

Jun 7, 1982

Appl. No.:

6/385746

Inventors:

Marcia E. Christy - Perkasie PA
Kenneth L. Shepard - West Point PA
Robert G. Strachan - Warrington PA
Sandor L. Varga - Harleysville PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07C10352

US Classification:

2601125R

Abstract:

There are disclosed metabolically protected linear analogs of the carboxy terminal pentapeptide fragment of the tridecapeptide, neurotensin.

US Patent:

41615212, Jul 17, 1979

Filed:

Jun 14, 1976

Appl. No.:

5/695348

Inventors:

Daniel F. Veber - Ambler PA
Frederick W. Holly - Glenside PA
Robert G. Strachan - Warrington PA
William J. Paleveda - Lansdale PA
Ruth F. Nutt - Green Lane PA
Ralph F. Hirschmann - Blue Bell PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 3700
C07C10352

US Classification:

424177

Abstract:

Somatostatin analogs having the structural formula: ##STR1## are prepared by controlled stepwise procedures starting with individual amino acid components. These peptides have the property of lowering blood glucose, inhibiting gastric secretion, inhibiting growth hormone release and inhibiting glucagon release in humans and animals.

US Patent:

44393598, Mar 27, 1984

Filed:

Jul 2, 1982

Appl. No.:

6/394750

Inventors:

Frederick W. Holly - late of Glenside PA
Marcia E. Christy - Perkasie PA
Kenneth L. Shepard - West Point PA
Robert G. Strachan - Warrington PA
Sandor L. Varga - Harleysville PA
Daniel F. Veber - Ambler PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07C10352

US Classification:

2601125R

Abstract:

There are disclosed cyclic octapeptide analogs of the tridecapeptide, neurotensin.

US Patent:

41305540, Dec 19, 1978

Filed:

Apr 8, 1975

Appl. No.:

5/566150

Inventors:

Frederick W. Holly - Glenside PA
William J. Paleveda - Lansdale PA
Robert G. Strachan - Warrington PA
Daniel F. Veber - Ambler PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07C10352
A61K 3700

US Classification:

2601125R

Abstract:

Somatostatin analog, hereinafter designated des(Ala. sup. 1 -Gly. sup. 2)desaminocys. sup. 3 -somatostatin, having the structure: ##STR1## is prepared by controlled stepwise procedures starting with individual amino acid components. This peptide has the property of lowering blood glucose, inhibiting gastric secretion and inhibiting growth hormone release in humans and animals.

US Patent:

41622480, Jul 24, 1979

Filed:

Apr 7, 1978

Appl. No.:

5/894266

Inventors:

Robert G. Strachan - Warrington PA
William J. Paleveda - Lansdale PA
Daniel F. Veber - Ambler PA
Frederick W. Holly - Glenside PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 3702
C07C10352

US Classification:

2601125S

Abstract:

Somatostatin analogs having the structural formula: Cyclo[(X). sub. j -(A). sub. k -(B). sub. 1 -Phe-Phe-(D- or L-)Trp-Lys-Thr-Phe-Thr-(C). sub. m ] Wherein X is ##STR1## and n=0 to 4; A is Lys, (. epsilon. -INOC) Lysine; B is Asn, Ala,. alpha. -aminobutyric acid; C is Ser, Gly; J, k, l and m are 0 to 1; with the proviso that j, k, l, and m are not all 1 and not all 0, Wherein the ring formed by the peptide backbone contains 24 to 33 atoms and the pharmaceutically acceptable non-toxic acid addition salts thereof are prepared by the solid phase method. These peptides have the property of inhibiting release of insulin, decreasing gastric secretion, inhibiting growth hormone release and inhibiting glucagon release in humans and animals.

US Patent:

40987779, Jul 4, 1978

Filed:

Mar 14, 1977

Appl. No.:

5/777226

Inventors:

Daniel F. Veber - Ambler PA
Robert G. Strachan - Warrington PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07C10352

US Classification:

2601125R

Abstract:

This invention is directed to the chemical process for the preparation of the polypeptide, pyroglutamyl-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn and to intermediates in said process. The polypeptide prepared by the present process is useful in the treatment of autoimmune diseases such as Lupus like pathology and specifically for the treatment of Lupus Erythematosus in man. This polypeptide is also useful for selectively stimulating T-cell activity in aging subjects.